<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Epoprostenol: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Epoprostenol: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Epoprostenol: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9411" href="/d/html/9411.html" rel="external">see "Epoprostenol: Drug information"</a> and <a class="drug drug_patient" data-topicid="11532" href="/d/html/11532.html" rel="external">see "Epoprostenol: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F165855"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Flolan;</li>
<li>Veletri</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866750"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Caripul;</li>
<li>Flolan</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1011254"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Prostaglandin</span></li></ul></div>
<div class="block don drugH1Div" id="F53462440"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Doses are expressed in units of <b>nanograms (ng)</b>/kg/minute.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ef4ac1d4-1150-4ef0-bdc6-5a9f0573103a">Pulmonary hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pulmonary hypertension:</b> Dosing regimens and efficacy results variable. <b>Note: </b>Drug administered by continuous IV infusion or inhalation; use precaution to verify dose and route of administration. Avoid abrupt withdrawal or sudden large dose reductions when discontinuing therapy to prevent rebound pulmonary hypertension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30614292']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30614292'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Preterm and Term Neonates:</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous IV infusion: Limited data available:</p>
<p style="text-indent:-2em;margin-left:8em;">Initial: 1 to 2 nanograms/kg/minute; titrate in 0.5 to 2 nanograms/kg/minute increments at intervals of at least 45 minutes until clinical goals are achieved or dose-limiting side effects occur; usual target dose: 20 nanograms/kg/minute; higher doses may be needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26534956','lexi-content-ref-30046179','lexi-content-ref-25006402','lexi-content-ref-35049017']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26534956','lexi-content-ref-30046179','lexi-content-ref-25006402','lexi-content-ref-35049017'])">Ref</a></span>). <b>Note</b>: Excessive epoprostenol can lead to a high-output state (hyperdynamic right ventricle with impact on cardiac output) and require a decrease in dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26534956']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26534956'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Inhalation: Very limited data available; optimal dose and titration not established; efficacy results vary with patient age and etiology of pulmonary hypertension; other factors that may impact efficacy include product formulation (eg, pH, dilution, stability) and the drug delivery system (eg, type of nebulizer, placement in ventilator circuit, ventilator settings) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28374138','lexi-content-ref-32973104']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28374138','lexi-content-ref-32973104'])">Ref</a></span>); refer to institutional policies and procedures.</p>
<p style="text-indent:-2em;margin-left:8em;">Continuous nebulization: Initial: 10 to 50 nanograms/kg/minute; titrate as needed based on patient response and treatment goals; reported maximum doses are variable and have been reported up to 100 nanograms/kg/minute; see institution-specific protocol. Dosing is based on retrospective studies and a case series; significant improvements in oxygenation index and echocardiogram findings have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30551229','lexi-content-ref-22558521','lexi-content-ref-12461501','lexi-content-ref-32973104']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30551229','lexi-content-ref-22558521','lexi-content-ref-12461501','lexi-content-ref-32973104'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F2521393"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Doses are expressed in units of <b>nanograms</b>
<b>(ng)</b>/kg/minute.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ef4ac1d4-1150-4ef0-bdc6-5a9f0573103a">Pulmonary hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pulmonary hypertension:</b> Limited data available: Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous IV infusion: Initial: 1 to 2 nanograms/kg/minute; titrate to clinical effect (eg, improvement in pulmonary pressures or right ventricular mechanics) or dose-limiting side effects (eg, nausea, diarrhea, jaw pain, bone pain, headache); average effective dose: 80 nanograms/kg/minute; dose range: 40 to &gt;150 nanograms/kg/minute in some patients. <b>Note</b>: Excessive epoprostenol can lead to a high-output state (hyperdynamic right ventricle with impact on cardiac output) and require a decrease in dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26534956']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26534956'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Inhalation: Very limited data available; efficacy results vary with patient age and etiology of pulmonary hypertension. Other factors that may impact efficacy include product formulation (eg, pH, dilution, stability) and the drug delivery system (eg, type of nebulizer, placement in ventilator circuit, ventilator settings) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28374138']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28374138'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous nebulization: 20 to 50 nanograms/kg/minute; dosing based on a small prospective trial of 14 children (median age: 54 months) with acute lung injury who received either aerosolized saline or inhaled epoprostenol administered in incremental doses (10, 20, 30, 40, and 50 nanograms/kg/minute); significant improvement of the oxygenation index was observed at the 30 nanograms/kg/minute dose level and values close to significant at the 20, 40, and 50 nanograms/kg/minute dose were observed; eight of the 14 children were considered responders to therapy with an improvement in oxygenation, and the calculated number needed to treat was 1.8 (95% CI, 1.2 to 3.2); during the trial, no significant changes in respiratory or systemic cardiovascular variables (eg, HR, MAP, arterial pH) or ventilator settings were reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15071401']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15071401'])">Ref</a></span>). A very small retrospective descriptive analysis (n=20, infants: n=7) using a dose of 50 nanograms/kg/minute reported minimal decrease in oxygenation index (baseline: 29.6 ± 15; with inhaled epoprostenol: 25.6 ± 17.8); however, the subset of term neonates (n=13) experienced significant improvement in oxygenation index and echocardiogram findings (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22558521']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22558521'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51108630"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51108631"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F165858"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9411" href="/d/html/9411.html" rel="external">see "Epoprostenol: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c0942e9d-43b7-4cbd-a1db-c41b17d28d52">Acute respiratory distress syndrome, moderate to severe, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute respiratory distress syndrome, moderate to severe, refractory (off-label use/route): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Based on limited data; optimal dosing strategy (eg, fixed-dose versus weight-based dosing) and titration unknown; titrate to lowest effective dose based on clinical response. There may be a dose-dependent improvement in oxygenation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10713012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10713012'])">Ref</a></span>); initiating at a high dose and titrating down may be preferred to improve oxygenation in unstable patients. Refer to institutional policies and procedures.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Example regimens include:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Fixed-dose:</b>
<b>Inhalation, continuous:</b> Initial: Use a 20,000 <b>ng</b>/mL solution and nebulize at a rate of 8 <b>mL</b>/hour; titrate down based on clinical response by reducing the concentration to 10,000 <b>ng</b>/mL while continuing to nebulize at a rate of 8 <b>mL</b>/hour; discontinue based on clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32133901','lexi-content-ref-35877207']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32133901','lexi-content-ref-35877207'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Weight-based dose:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Inhalation, continuous:</b> Initial: 50 <b>ng</b>/kg/minute (using ideal body weight); titrate down by 10 <b>ng</b>/kg/minute every 1 to 4 hours based on clinical response; maximum dose: 50 <b>ng</b>/kg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32133901','lexi-content-ref-35877207','lexi-content-ref-31372630','lexi-content-ref-23683572','lexi-content-ref-26668204']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32133901','lexi-content-ref-35877207','lexi-content-ref-31372630','lexi-content-ref-23683572','lexi-content-ref-26668204'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>OR</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Inhalation, continuous:</b> Initial: 10 <b>ng</b>/kg/minute (using ideal body weight); titrate up by 10 to 20 <b>ng</b>/kg/minute every 15 minutes based on clinical response; once patient has stabilized and the decision to discontinue therapy, titrate down by 10 <b>ng</b>/kg/minute every 2 hours based on clinical response; maximum dose: 50 <b>ng</b>/kg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26187741','lexi-content-ref-31729256']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26187741','lexi-content-ref-31729256'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="58a3cd23-4fbc-4ca7-8c74-26fd785e3679">Acute vasodilator testing in patients with pulmonary arterial hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute vasodilator testing in patients with pulmonary arterial hypertension (off-label use):</b>
<b>Note:</b> Acute vasodilator testing is recommended in patients with idiopathic, heritable, or drug-induced pulmonary arterial hypertension to assess eligibility for treatment with a calcium channel blocker (eg, ER nifedipine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19389575','lexi-content-ref-36017548']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19389575','lexi-content-ref-36017548'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Initial: 2 ng/kg/minute; increase dose in increments of 2 ng/kg/minute every 10 to 15 minutes; dosing range during testing: 2 to 12 <b>ng</b>/kg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19389575','lexi-content-ref-36017548']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19389575','lexi-content-ref-36017548'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7c404650-aab2-4e9c-9a4a-aad11cf6c972">Postcardiothoracic surgery complicated by pulmonary hypertension, right ventricular dysfunction, or refractory hypoxemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Postcardiothoracic surgery complicated by pulmonary hypertension, right ventricular dysfunction, or refractory hypoxemia (off-label use/route): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Based on limited data, optimal dosing strategy and titration remains unknown; titrate to lowest effective dose based on response and tolerability; refer to institutional policies and procedures.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Fixed-dose: Inhalation, continuous: </b>Use a 20,000 <b>ng</b>/mL solution and nebulize at a constant rate of 8 mL/hour; titrate down every 30 minutes to 4 hours based on clinical response by reducing the solution concentration to 10,000 <b>ng</b>/mL while continuing to nebulize at a constant rate of 8 mL/hour for every titration; titrate down further after another 30 minutes to 4 hours by reducing the solution concentration to 5,000 <b>ng</b>/mL, then 2,500 <b>ng</b>/mL; discontinue when the patient is clinically stable on the 2,500 <b>ng</b>/mL solution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15052203','lexi-content-ref-26438636']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15052203','lexi-content-ref-26438636'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Weight-based dose:</b>
<b>Inhalation, continuous: </b>Initial: 10 to 50 <b>ng</b>/kg/minute based on ideal body weight; titrate by increasing or decreasing dose in increments of 10 <b>ng</b>/kg/minute every 30 minutes to 2 hours as tolerated based on clinical response; maximum dose: 50 <b>ng</b>/kg/minute. Weight-based dosing is extrapolated from studies in patients with acute respiratory distress syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26187741','lexi-content-ref-24734313','lexi-content-ref-28543813','lexi-content-ref-23683572']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26187741','lexi-content-ref-24734313','lexi-content-ref-28543813','lexi-content-ref-23683572'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9b6777ad-1508-4cf7-924a-99d10f0a73e1">Pulmonary arterial hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pulmonary arterial hypertension:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Consult a pulmonary arterial hypertension specialist for all management decisions; choice of therapy is dependent on etiology, risk stratification, cardiopulmonary comorbidities, and response to other agents. Prostacyclin analogues are generally reserved for initial therapy in high-risk patients or used as adjunctive therapy in patients who continue to deteriorate on oral agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30660783','lexi-content-ref-36017548']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30660783','lexi-content-ref-36017548'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>
<i>Initial:</i> 2 <b>ng/</b>kg/minute; a lower initial dose may be used if patient is intolerant of starting dose. Increase dose in increments of 1 to 2 <b>ng</b>/kg/minute at intervals of ≥15 minutes until dose-limiting side effects (eg, flushing, jaw pain, headache, hypotension, hypoxemia, nausea) are noted or further dose increase is not clinically warranted. Usual dose when used as monotherapy: 25 to 40 <b>ng</b>/kg/minute, however, significant patient variability in optimal dose exists (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19389575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19389575'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Dose adjustment during chronic phase of treatment:</i></p>
<p style="text-indent:-2em;margin-left:6em;">If symptoms persist or recur following initiation of therapy, increase dose in 1 to 2<b> ng</b>/kg/minute increments at intervals of ≥15 minutes. May also increase dose at intervals of 24 to 48 hours or longer (eg, every 1 to 2 weeks). The need for increased doses should be expected with chronic use and occur more frequently during the first few months after initiation of therapy.</p>
<p style="text-indent:-2em;margin-left:6em;">In case of dose-limiting adverse events (eg, hypotension, hypoxemia, severe nausea, vomiting), decrease dose in 2 <b>ng</b>/kg/minute decrements at intervals of ≥15 minutes until dose-limiting effects resolve. Avoid abrupt withdrawal or sudden large dose reductions. Adverse effects may resolve without dosage adjustment.</p>
<p style="text-indent:-2em;margin-left:6em;">Lung transplant: In patients receiving lung transplant, epoprostenol may be tapered after cardiopulmonary bypass has been initiated.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Transitioning from SubQ treprostinil to IV epoprostenol:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Transition should only occur under supervision of a clinician with expertise in pulmonary arterial hypertension and in a hospital setting to closely monitor vital signs, hemodynamic response, and clinical symptoms. Transition protocols are institution specific and must be individualized to patient needs. The following is only one example (utilized in a limited number of patients) for transitioning from SubQ treprostinil to IV epoprostenol. In general, epoprostenol dose is increased gradually while simultaneously decreasing the treprostinil dose to balance clinical worsening and dose limiting side effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24084219','lexi-content-ref-32115272','lexi-content-ref-15755791']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24084219','lexi-content-ref-32115272','lexi-content-ref-15755791'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Treprostinil dose reduction: First, reduce SubQ treprostinil by 5 <b>ng</b>/kg/minute, then initiate IV epoprostenol based on instructions below. Continue to reduce SubQ treprostinil dose by 5 <b>ng</b>/kg/minute every 5 hours; when SubQ treprostinil dose is reduced to ≤ 8 <b>ng</b>/kg/minute, then discontinue therapy completely 5 hours later (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32115272']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32115272'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Epoprostenol dose escalation: 2 hours <b>after</b> the initial SubQ treprostinil dose reduction, begin IV epoprostenol 2 <b>ng</b>/kg/minute; titrate by increasing dose 2 <b>ng</b>/kg/minute every 2 hours; if dose limiting side effects occur (eg, flushing, jaw pain, headache, hypotension, nausea), stop up-titration and consult the pulmonary arterial hypertension specialist overseeing the transition between agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32115272']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32115272'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50992059"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50989381"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F165830"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing (23% to 58%), tachycardia (1% to 43%), hypotension (13% to 27%), chest pain (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (46% to 83%), dizziness (8% to 83%), chills (≤25%), anxiety (≤21%), nervousness (≤21%), hyperesthesia (≤12%), hypoesthesia (≤12%), paresthesia (≤12%), agitation (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Dermal ulcer (39%), eczema (≤10% to ≤25%), skin rash (≤10% to ≤25%), urticaria (≤10% to ≤25%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea and vomiting (32% to 67%), anorexia (25% to 66%), diarrhea (37% to 50%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Sepsis (≤25%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Musculoskeletal pain (3% to 84%), arthralgia (≤84%), neck pain (≤84%), jaw pain (54% to 75%), myalgia (44%), hyperkinesia (≤21%), tremor (≤21%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Flu-like symptoms (≤25%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (≤25%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (5%), dyspepsia (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Anemia, cardiac failure, fatigue, hemorrhage, hepatic failure, hypersplenism, hyperthyroidism, increased pulmonary artery pressure, pallor, pancytopenia, pulmonary edema, pulmonary embolism, splenomegaly, thrombocytopenia</p></div>
<div class="block coi drugH1Div" id="F165844"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to epoprostenol, to structurally related compounds, or any component of the formulation; chronic use in patients with heart failure due to severe left ventricular systolic dysfunction; chronic use in patients who develop pulmonary edema during dose initiation (Caripul [Canadian product], Flolan [Canadian product], and Veletri only).</p></div>
<div class="block war drugH1Div" id="F165827"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary edema: Some patients with PAH have developed pulmonary edema during dosing adjustment and acute vasodilator testing (an off-label use), which may be associated with concomitant heart failure (LV systolic dysfunction with significantly elevated left heart filling pressures) or pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis. If pulmonary edema develops during therapy initiation, discontinue and do not readminister.</p>
<p style="text-indent:-2em;margin-left:4em;">• Rebound pulmonary hypertension: Avoid abrupt interruptions or large sudden reductions in dosage; may result in rebound pulmonary hypertension (eg, dyspnea, hypoxia, dizziness, asthenia). Back-up medication and pump and infusion sets in the patient-care area are essential to prevent treatment interruptions.</p>
<p style="text-indent:-2em;margin-left:4em;">• Vasodilation: Systemic epoprostenol is a potent pulmonary and systemic vasodilator and can cause hypotension and other reactions, such as flushing, nausea, vomiting, dizziness, and headache. Inhaled administration may result in minimal systemic absorption and potentially decrease risk of vasodilation when compared to systemic therapy. Monitor BP and symptoms regularly during initiation and after dose change.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Conditions that increase bleeding risk: Systemic epoprostenol is a potent inhibitor of platelet aggregation. Use with caution in patients with other risk factors for bleeding. There is insufficient evidence to suggest that inhaled epoprostenol increases the risk of bleeding (Buckley 2010; Rao 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate Use: Initiation or transition to epoprostenol requires specialized cardiopulmonary monitoring in a critical care setting where clinicians are experienced in advanced management of pulmonary arterial hypertension.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infection: Chronic continuous IV infusion of epoprostenol via a chronic indwelling central venous catheter (CVC) has been associated with local infections and serious blood stream infections.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878445"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Although the use of anticoagulants in adult patients with primary pulmonary hypertension has been shown to improve survival, such efficacy has not been demonstrated in pediatric patients. Some studies have reported the routine use of warfarin in pediatric patients receiving long-term (chronic) infusions of epoprostenol for pulmonary hypertension (Barst 1999; Rosenzweig 1999), while other studies have routinely discontinued anticoagulants prior to the initiation of epoprostenol therapy (Higenbottam 1993). Epoprostenol is a potent inhibitor of platelet aggregation; monitor patients for bleeding, especially those with other risk factors or medications which may increase the risk for hemorrhage. Further studies are needed to assess the risks and benefits of routine anticoagulation in pediatric patients treated with epoprostenol.</p></div>
<div class="block foc drugH1Div" id="F165839"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Flolan: 0.5 mg (1 ea); 1.5 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Veletri: 0.5 mg (1 ea); 1.5 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5 mg (1 ea [DSC]); 1.5 mg (1 ea [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5 mg (1 ea); 1.5 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F165823"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323130"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Epoprostenol Sodium Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg (per each): $28.10</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.5 mg (per each): $56.21</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Flolan Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg (per each): $22.43</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.5 mg (per each): $54.17</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Veletri Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg (per each): $29.51</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.5 mg (per each): $59.02</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866751"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Caripul: 0.5 mg (1 ea); 1.5 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Flolan: 0.5 mg (1 ea); 1.5 mg (1 ea)</p></div>
<div class="block accres drugH1Div" id="F11233737"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Orders for epoprostenol are distributed by two sources in the United States. Information on orders or reimbursement assistance may be obtained from either Accredo Health, Inc (1-866-344-4874) or CVS Caremark (1-877-242-2738). </p></div>
<div class="block admp drugH1Div" id="F52612702"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Continuous IV infusion: For IV use via an infusion pump. Use infusion sets with an in-line 0.22 micron filter. Must be infused through a central venous catheter; peripheral infusion may be used temporarily until central line is established. Infuse through a dedicated lumen exclusive of any other drugs; consider a multilumen catheter if other IV medications are routinely administered. Avoid abrupt withdrawal, interruptions in delivery, or sudden large reductions in dosing. Patients should have access to a back-up infusion pump and infusion sets. Patients may be discharged using an ambulatory infusion pump. Appropriate ambulatory infusion pump should be small and lightweight; be able to adjust infusion rates in 2 nanograms/kg/minute increments; have occlusion, end of infusion, and low battery alarms; have ±6% accuracy of the programmed rate; and have positive continuous or pulsatile pressure with intervals ≤3 minutes between pulses. The reservoir should be made of polypropylene, polyvinyl chloride, or glass. Immediate access to back-up pump, infusion sets, and medication is essential to prevent treatment interruptions. Consult manufacturer's labeling for infusion rate example calculations.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Flolan-specific administration considerations:</i> Avoid administration materials containing polyethylene terephthalate (PET) or polyethylene terephthalate glycol (PETG); consult administration set manufacturer to confirm compatibility with highly alkaline solutions (eg, pH 12 sterile diluent for Flolan).</p>
<p style="text-indent:-2em;margin-left:2em;">Inhalation: Nebulization: Administer via nebulization device connected as close to the mask or endotracheal tube in the inspiratory limb of the noninvasive ventilation (ie, BiPAP) or invasive ventilation circuit, respectively (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22558521']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22558521'])">Ref</a></span>). Administration via an anesthesia machine intraoperatively with inhaled nitric oxide has also been described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30472016']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30472016'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F165841"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> For IV use via an infusion pump. Use infusion sets with an in-line 0.22 micron filter. When administered on an ongoing basis, must be infused through a central venous catheter. Peripheral infusion may be used temporarily until central line is established. Do not administer as a bolus injection. Avoid abrupt withdrawal (including interruptions in delivery) or sudden large reductions in dosing. The ambulatory infusion pump should be small and lightweight, be able to adjust infusion rates in 2 ng/kg/minute increments, have occlusion, end of infusion, and low battery alarms, have ± 6% accuracy of the programmed rate, and have positive continuous or pulsatile pressure with intervals ≤3 minutes between pulses. The reservoir should be made of polyvinyl chloride, polypropylene, or glass. Immediate access to back up pump, infusion sets and medication is essential to prevent treatment interruptions. Consult manufacturer's labeling for infusion rate example calculations.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Flolan-specific administration considerations:</i> Avoid administration materials containing polyethylene terephthalate (PET) or polyethylene terephthalate glycol (PETG); consult administration set manufacturer to confirm compatibility with highly alkaline solutions (eg, pH 12 sterile diluent for Flolan).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Inhalation, continuous (off-label route):</b> May be administered via jet nebulizer connected to the inspiratory limb of the ventilator near the endotracheal tube or via face mask with a Venturi attachment for aerosolization with a bypass oxygen flow of 2 to 3 L/minute, or via high flow nasal cannula or noninvasive positive pressure ventilation with an oxygen flow of 50 L/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29890848','lexi-content-ref-15052203','lexi-content-ref-24734313']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29890848','lexi-content-ref-15052203','lexi-content-ref-24734313'])">Ref</a></span>). <b>Note:</b> Flolan or Veletri may be used for this route of administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29749260','lexi-content-ref-29336971','lexi-content-ref-26668204']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29749260','lexi-content-ref-29336971','lexi-content-ref-26668204'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F165850"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Flolan: </b>Prior to use, store intact vials and diluent at 15°C to 25°C (59°F to 77°F); do not freeze. Protect from light. Following reconstitution, solution must be stored at 2°C to 8°C (36°F to 46°F) if not used immediately; do not freeze. Protect from light. Freshly prepared reconstituted solutions or reconstituted solutions that have been stored at 2°C to 8°C (36°F to 46°F) for no longer than 8 days can be administered up to 48 hours at up to 25°C (77°F); 36 hours at up to 30°C (86°F); 24 hours at up to 35°C (95°F); 12 hours at up to 40°C (104°F); discard any unused solution after these times.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Veletri and Caripul [Canadian product]: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Veletri:</b> Prior to use, store intact vials at 20°C to 25°C (68°F to 77°F); do not freeze. Protect from light. Reconstituted vials must be further diluted prior to use.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Caripul [Canadian product]: </b>Prior to use, store intact vials at 15°C to 30°C (59°F to 86°F); do not freeze. Reconstituted vials must be further diluted prior to use.</p>
<p style="text-indent:-2em;margin-left:4em;">Reconstituted solutions of Veletri or Caripul immediately diluted with NS to a final concentration within a drug delivery reservoir may be administered immediately or stored at 2°C to 8°C (36°F to 46°F) for up to 8 days; do not freeze. Protect from light.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>If administered immediately,</b> the following maximum durations of administration at room temperature (25°C [77°F]) according to solution concentration are recommended:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>US labeling (Veletri):</i></p>
<p style="text-indent:-2em;margin-left:10em;">3,000 to &lt;15,000 ng/mL: 48 hours</p>
<p style="text-indent:-2em;margin-left:10em;">15,000 to &lt;60,000 ng/mL: 48 hours</p>
<p style="text-indent:-2em;margin-left:10em;">≥60,000 ng/mL: 72 hours</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Canadian labeling (Caripul):</i></p>
<p style="text-indent:-2em;margin-left:10em;">3,000 to &lt;15,000 ng/mL: 48 hours</p>
<p style="text-indent:-2em;margin-left:10em;">≥15,000: 48 hours</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>If stored at 2°C to 8°C (36°F to 46°F) for up to 8 days (Veletri or Caripul), </b> the following maximum durations of administration at room temperature (25°C [77°F]) according to solution concentration are recommended:</p>
<p style="text-indent:-2em;margin-left:8em;">3,000 to &lt;15,000 ng/mL: 24 hours</p>
<p style="text-indent:-2em;margin-left:8em;">15,000 to &lt;60,000 ng/mL: 48 hours</p>
<p style="text-indent:-2em;margin-left:8em;">≥60,000 ng/mL: 48 hours</p>
<p style="text-indent:-2em;margin-left:6em;">Short excursions at 40°C (104°F) are permitted as follows:</p>
<p style="text-indent:-2em;margin-left:8em;">Solution concentration &lt;15,000 ng/mL: Up to 2 hours</p>
<p style="text-indent:-2em;margin-left:8em;">Solution concentration 15,000 to &lt;60,000 ng/mL: Up to 4 hours</p>
<p style="text-indent:-2em;margin-left:8em;">Solution concentration ≥60,000 ng/mL: Up to 8 hours</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>The following maximum durations of administration at temperatures &gt;25°C to 40°C (&gt;77°F up to 104°F) administered either immediately or after up to 8 days storage at 2°C to 8°C (36°F to 46°F) according to solution concentration are recommended: </b></p>
<p style="text-indent:-2em;margin-left:6em;">Use at temperature &gt;25°C to 30°C (&gt;77°F up to 86°F):</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>US labeling (Veletri):</i></p>
<p style="text-indent:-2em;margin-left:10em;">&lt;60,000 ng/mL: 24 hours</p>
<p style="text-indent:-2em;margin-left:10em;">≥60,000 ng/mL: 48 hours</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Canadian labeling (Caripul): </i> All concentrations: 24 hours</p>
<p style="text-indent:-2em;margin-left:6em;">Use at temperature up to 40°C (104°F):</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>US labeling (Veletri):</i> ≥60,000 ng/mL: 24 hours (immediately administered after preparation)</p></div>
<div class="block usep drugH1Div" id="F53566703"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of pulmonary arterial hypertension (PAH) (WHO Group I) in patients with NYHA Class III or IV symptoms to improve exercise capacity (FDA approved in adults). <b>Note:</b> According to adult treatment guidelines from the Fifth World Symposium on Pulmonary Hypertension (WSPH) and the American College of Chest Physicians (ACCP), continuous IV epoprostenol is recommended as first-line therapy in PAH patients with WHO-FC IV symptoms (ACCP [Taichman 2014]; WSPH [Galiè 2013]); has also been used to treat severe PAH with right ventricular failure</p></div>
<div class="block mst drugH1Div" id="F5174529"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299275"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F165832"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Prostacyclin Analogues may enhance the antiplatelet effect of Agents with Antiplatelet Properties. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticoagulants: Prostacyclin Analogues may enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: Prostacyclin Analogues may enhance the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Digoxin: Epoprostenol may increase the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thrombolytic Agents: May enhance the adverse/toxic effect of Prostacyclin Analogues. Specifically, the antiplatelet effects of prostacyclin analogues may lead to an increased risk of bleeding when combined with thrombolytic agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F2521390"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Information related to the use of epoprostenol in pregnancy is limited (Geohas 2003; Kawabe 2018; Martinez 2013; Smith 2012; Timofeev 2013); however, the manufacturer notes adverse maternal or fetal outcomes have not been associated with its use based on the available data.</p>
<p style="text-indent:0em;margin-top:2em;">Untreated pulmonary arterial hypertension (PAH) is associated with adverse pregnancy outcomes, including heart failure, stroke, preterm delivery, and maternal and fetal death.</p></div>
<div class="block mopp drugH1Div" id="F53566704"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor for improvements in pulmonary function, decreased exertional dyspnea, fatigue, syncope and chest pain, blood pressure, pulmonary vascular resistance, pulmonary arterial pressure, right ventricular function/mechanics, and quality of life. Monitor platelets and signs and symptoms of bleeding. Following establishment of a new chronic infusion rate, measure standing and supine blood pressure for several hours if appropriate. In addition, the pump device and catheters should be monitored frequently to avoid "system"-related failure. Monitor arterial pressure; assess all vital functions. Hypoxia, flushing, and tachycardia may indicate overdose. Monitor for crystallization within the nebulizer (Gillis 2018).</p></div>
<div class="block pha drugH1Div" id="F165826"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Epoprostenol is also known as prostacyclin and PGI<sub>2</sub>. It is a strong vasodilator of all vascular beds. In addition, it is a potent endogenous inhibitor of platelet aggregation. The reduction in platelet aggregation results from epoprostenol's activation of intracellular adenylate cyclase and the resultant increase in cyclic adenosine monophosphate concentrations within the platelets. Additionally, it is capable of decreasing thrombogenesis and platelet clumping in the lungs by inhibiting platelet aggregation.</p></div>
<div class="block phk drugH1Div" id="F165843"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Rapidly hydrolyzed; subject to some enzymatic degradation; forms two active metabolites (6-keto-prostaglandin F<sub>1</sub>α and 6,15-diketo-13,14-dihydro-prostaglandin F<sub>1</sub>α) with minimal activity and 14 inactive metabolites.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ≤6 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (84%); feces (4%).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038611"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Flolan</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Epoprostenol Normon | Veletri</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Dynovas | Flolan</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Epoprostenol myx | Epoprostenol sun | Flolan | Veletri</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Epoprostenol | Flolan | Veletri</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Veletri</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Veletri</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Flolan | Veletri</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Epoprostenol Panpharma | Epoprostenol Rotexmedica | Veletri</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Dynovase | Epoprostenol Normon | Epoprostenol sandoz | Epoprostenol sun | Epoprostenol Teva | Flolan | Veletri</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Epoprostenol Arrow | Epoprostenol Panpharma | Epoprostenol sandoz | Flolan | Veletri</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Cyclo prostin | Epoprostenol | Flolan | Veletri</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Veletri</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Flolan | Veletri</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Caripul | Epoprostenolo PH&amp;T | Epoprostenolo sun | Flolan</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Epoprostenol | Flolan</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Flolan</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Epoprostenol | Flolan | Veletri</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Epoprostenol campuspharma | Flolan | Veletri</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Veletri</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Epoprostenol drehm | Flolan | Veletri</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Epoprostenol</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Veletri</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Epoprostenol</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Veletri</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Epoprostenol campuspharma | Epoprostenol ebb</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Flolan</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Flolan</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Veletri</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Veletri</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-26534956">
<a name="26534956"></a>Abman SH, Hansmann G, Archer SL, et al. Pediatric pulmonary hypertension: guidelines from the American Heart Association and American Thoracic Society. <i>Circulation</i>. 2015;132(21):2037-2099.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/26534956/pubmed" id="26534956" target="_blank">26534956</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30046179">
<a name="30046179"></a>Ahmad KA, Banales J, Henderson CL, Ramos SE, Brandt KM, Powers GC. Intravenous epoprostenol improves oxygenation index in patients with persistent pulmonary hypertension of the newborn refractory to nitric oxide. <i>J Perinatol</i>. 2018;38(9):1212-1219. doi:10.1038/s41372-018-0179-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/30046179/pubmed" id="30046179" target="_blank">30046179</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24084219">
<a name="24084219"></a>Alkukhun L, Bair ND, Dweik RA, Tonelli AR. Subcutaneous to intravenous prostacyclin analog transition in pulmonary hypertension. <i>J Cardiovasc Pharmacol</i>. 2014;63(1):4-8. doi:10.1097/FJC.0000000000000018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/24084219/pubmed" id="24084219" target="_blank">24084219</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26187741">
<a name="26187741"></a>Ammar MA, Bauer SR, Bass SN, Sasidhar M, Mullin R, Lam SW. Noninferiority of Inhaled Epoprostenol to Inhaled Nitric Oxide for the Treatment of ARDS. <i>Ann Pharmacother</i>. 2015;49(10):1105-1112. doi:10.1177/1060028015595642.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/26187741/pubmed" id="26187741" target="_blank">26187741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29890848">
<a name="29890848"></a>Ammar MA, Sasidhar M, Lam SW. Inhaled epoprostenol through noninvasive routes of ventilator support systems. <i>Ann Pharmacother</i>. 2018;52(12):1173‐1181. doi:10.1177/1060028018782209<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/29890848/pubmed" id="29890848" target="_blank">29890848</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2869919">
<a name="2869919"></a>Barst RJ, "Pharmacologically Induced Pulmonary Vasodilatation in Children and Young Adults With Primary Pulmonary Hypertension," <i>Chest</i>, 1986, 89(4):497-503.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/2869919/pubmed" id="2869919" target="_blank">2869919</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10069788">
<a name="10069788"></a>Barst RJ, Maislin G, and Fishman AP, “Vasodilator Therapy for Primary Pulmonary Hypertension in Children,” <i>Circulation</i>, 1999, 99(9):1197-208.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/10069788/pubmed" id="10069788" target="_blank">10069788</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8532025">
<a name="8532025"></a>Barst RJ, Rubin LJ, Long WA, et al, “A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) With Conventional Therapy for Primary Pulmonary Hypertension. The Primary Pulmonary Hypertension Study Group,” <i>N Engl J Med</i>, 1996, 334(5):296-302.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/8532025/pubmed" id="8532025" target="_blank">8532025</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30551229">
<a name="30551229"></a>Berger-Caron F, Piedboeuf B, Morissette G, et al. Inhaled epoprostenol for pulmonary hypertension treatment in neonates: a 12-year experience. <i>Am J Perinatol</i>. 2019;36(11):1142-1149. doi:10.1055/s-0038-1676483<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/30551229/pubmed" id="30551229" target="_blank">30551229</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22806762">
<a name="22806762"></a>Bishop BM, Mauro VF, Khouri SJ. Practical considerations for the pharmacotherapy of pulmonary arterial hypertension. <i>Pharmacotherapy</i>. 2012;32(9):838-855. doi: 10.1002/j.1875-9114.2012.01114.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/22806762/pubmed" id="22806762" target="_blank">22806762</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35952768">
<a name="35952768"></a>Bosch NA, Law AC, Vail EA, et al. Inhaled nitric oxide vs epoprostenol during acute respiratory failure: an observational target trial emulation. <i>Chest</i>. 2022;162(6):1287-1296. doi:10.1016/j.chest.2022.08.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/35952768/pubmed" id="35952768" target="_blank">35952768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22558521">
<a name="22558521"></a>Brown AT, Gillespie JV, Miquel-Verges F, et al. Inhaled epoprostenol therapy for pulmonary hypertension: Improves oxygenation index more consistently in neonates than in older children. <i>Pulm Circ</i>. 2012;2(1):61-66.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/22558521/pubmed" id="22558521" target="_blank">22558521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32133901">
<a name="32133901"></a>Buckley MS, Agarwal SK, Garcia-Orr R, Saggar R, MacLaren R. Comparison of fixed-dose inhaled epoprostenol and inhaled nitric oxide for acute respiratory distress syndrome in critically ill adults. <i>J Intensive Care Med</i>. 2021;36(4):466-476. doi:10.1177/0885066620906800<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/32133901/pubmed" id="32133901" target="_blank">32133901</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20575636">
<a name="20575636"></a>Buckley MS, Feldman JP. Inhaled epoprostenol for the treatment of pulmonary arterial hypertension in critically ill adults. <i>Pharmacotherapy</i>. 2010;30(7):728‐740. doi:10.1592/phco.30.7.728<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/20575636/pubmed" id="20575636" target="_blank">20575636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35877207">
<a name="35877207"></a>Buckley MS, Mendez A, Radosevich JJ, Agarwal SK, MacLaren R. Comparison of 2 different inhaled epoprostenol dosing strategies for acute respiratory distress syndrome in critically ill adults: weight-based vs fixed-dose administration. <i>Am J Health Syst Pharm</i>. Published online July 25, 2022. doi:10.1093/ajhp/zxac192<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/35877207/pubmed" id="35877207" target="_blank">35877207</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Caripul.1">
<a name="Caripul.1"></a>Caripul (epoprostenol) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; December 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7840058">
<a name="7840058"></a>Cremona G and Higenbottam T, “Role of Prostacyclin in the Treatment of Primary Pulmonary Hypertension,” <i>Am J Cardiol</i>, 1995, 75(3):67A-71A.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/7840058/pubmed" id="7840058" target="_blank">7840058</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15071401">
<a name="15071401"></a>Dahlem P, van Aalderen WM, de Neef M, Dijkgraaf MG, Bos AP. Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. <i>Crit Care Med</i>. 2004;32(4):1055-1060.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/15071401/pubmed" id="15071401" target="_blank">15071401</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31372630">
<a name="31372630"></a>Davis SL, Crow JR, Fan JR, et al. Use and costs of inhaled nitric oxide and inhaled epoprostenol in adult critically ill patients: a quality improvement project. Am J Health Syst Pharm. 2019;76(18):1413-1419. doi:10.1093/ajhp/zxz151<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/31372630/pubmed" id="31372630" target="_blank">31372630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28374138">
<a name="28374138"></a>Davis MD, Donn SM, Ward RM. Administration of inhaled pulmonary vasodilators to the mechanically ventilated neonatal patient. <i>Paediatr Drugs</i>. 2017;19(3):183-192.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/28374138/pubmed" id="28374138" target="_blank">28374138</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15052203">
<a name="15052203"></a>De Wet CJ, Affleck DG, Jacobsohn E, et al, “Inhaled Prostacyclin is Safe, Effective, and Affordable in Patients with Pulmonary Hypertension, Right Heart Dysfunction, and Refractory Hypoxemia After Cardiothoracic Surgery,” <i>J Thorac Cardiovasc Surg</i>, 2004, 127(4):1058-67.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/15052203/pubmed" id="15052203" target="_blank">15052203</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24734313">
<a name="24734313"></a>Dzierba AL, Abel EE, Buckley MS, Lat I. A review of inhaled nitric oxide and aerosolized epoprostenol in acute lung injury or acute respiratory distress syndrome. <i>Pharmacotherapy</i>. 2014;34(3):279-290. doi:10.1002/phar.1365<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/24734313/pubmed" id="24734313" target="_blank">24734313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8960484">
<a name="8960484"></a>Eronen M, Pohjavuori M, Andersson S, et al, "Prostacyclin Treatment for Persistent Pulmonary Hypertension of the Newborn," <i>Pediatr Cardiol</i>, 1997, 18(1):3-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/8960484/pubmed" id="8960484" target="_blank">8960484</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15725144">
<a name="15725144"></a>Fattouch K, Sbraga F, Bianco G, et al. Inhaled prostacyclin, nitric oxide, and nitroprusside in pulmonary hypertension after mitral valve replacement. <i>J Card Surg</i>. 2005;20(2):171‐176. doi:10.1111/j.0886-0440.2005.200383w.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/15725144/pubmed" id="15725144" target="_blank">15725144</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Flolan.1">
<a name="Flolan.1"></a>Flolan (epoprostenol) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline Inc; October 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Flolan.2">
<a name="Flolan.2"></a>Flolan (epoprostenol) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Inc; February 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24355643">
<a name="24355643"></a>Galiè N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension. <i>J Am Coll Cardiol</i>. 2013;62(25 Suppl):D60-D72. doi:10.1016/j.jacc.2013.10.031.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/24355643/pubmed" id="24355643" target="_blank">24355643</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12970054">
<a name="12970054"></a>Geohas C, McLaughlin VV. Successful management of pregnancy in a patient with eisenmenger syndrome with epoprostenol. <i>Chest</i>. 2003;124(3):1170-1173.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/12970054/pubmed" id="12970054" target="_blank">12970054</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29436464">
<a name="29436464"></a>Gillis HC, Fischer G, Gupta S. Treatment of pulmonary hypertension with inhaled agents in the pediatric intensive care unit. <i>Am J Health Syst Pharm</i>. 2018;75(4):171-172. doi:10.2146/ajhp170353<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/29436464/pubmed" id="29436464" target="_blank">29436464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15984391">
<a name="15984391"></a>Golzand E, Bar-Oz B, and Arad I, "Intravenous Prostacyclin in the Treatment of Persistent Pulmonary Hypertension of the Newborn Refractory to Inhaled Nitric Oxide," <i>Isr Med Assoc J</i>, 2005, 7(6):408-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/15984391/pubmed" id="15984391" target="_blank">15984391</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24103713">
<a name="24103713"></a>Groves DS, Blum FE, Huffmyer JL, et al. Effects of early inhaled epoprostenol therapy on pulmonary artery pressure and blood loss during LVAD placement. <i>J Cardiothorac Vasc Anesth</i>. 2014;28(3):652‐660. doi:10.1053/j.jvca.2013.05.028<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/24103713/pubmed" id="24103713" target="_blank">24103713</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29749260">
<a name="29749260"></a>Hawn JM, Wanek M, Bauer SR, et al. Effectiveness, safety, and economic comparison of two inhaled epoprostenol products (Flolan and Veletri) in cardiothoracic surgery patients. <i>Ann Pharmacother</i>. 2018;52(10):956‐964. doi:10.1177/1060028018776432<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/29749260/pubmed" id="29749260" target="_blank">29749260</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31729256">
<a name="31729256"></a>Hawn JM, Bauer SR, Wanek MR, et al. Effectiveness, safety, and economic comparison of inhaled epoprostenol brands, Flolan and Veletri, in acute respiratory distress syndrome. <i>Ann Pharmacother</i>. 2020;54(5):434-441. doi:10.1177/1060028019888853<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/31729256/pubmed" id="31729256" target="_blank">31729256</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Higenbottam.1">
<a name="Higenbottam.1"></a>Higenbottam TW, Spiegelhalter D, Scott JP, et al, “Prostacyclin (Epoprostenol) and Heart-Lung Transplantation as Treatments for Severe Pulmonary Hypertension,” <i>Br Heart J</i>, 1994, 70:366-70.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017548">
<a name="36017548"></a>Humbert M, Kovacs G, Hoeper MM, et al; ESC/ERS Scientific Document Group. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension.<i> Eur Heart J</i>. 2022;43(38):3618-3731. doi:10.1093/eurheartj/ehac237<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/36017548/pubmed" id="36017548" target="_blank">36017548</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3552006">
<a name="3552006"></a>Jones DK, Higenbottam TW, Wallwork J. Treatment of primary pulmonary hypertension intravenous epoprostenol (prostacyclin). <i>Br Heart J</i>. 1987;57(3):270-278. doi:10.1136/hrt.57.3.270<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/3552006/pubmed" id="3552006" target="_blank">3552006</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29321410">
<a name="29321410"></a>Kawabe A, Nakano K, Aiko Y, et al. Successful management of pregnancy in a patient with systemic lupus erythematosus-associated pulmonary arterial hypertension. <i>Intern Med</i>. 2018;57(11):1655-1659. doi: 10.2169/internalmedicine.0033-17.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/29321410/pubmed" id="29321410" target="_blank">29321410</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12461501">
<a name="12461501"></a>Kelly LK, Porta NF, Goodman DM, Carroll CL, Steinhorn RH. Inhaled prostacyclin for term infants with persistent pulmonary hypertension refractory to inhaled nitric oxide. <i>J Pediatr</i>. 2002;141(6):830-832.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/12461501/pubmed" id="12461501" target="_blank">12461501</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1883670">
<a name="1883670"></a>Kermode J, Butt W, and Shann F, "Comparison Between Prostaglandin E1 and Epoprostenol (Prostacyclin) in Infants After Heart Surgery," <i>Br Heart J</i>, 1991, 66(2):175-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/1883670/pubmed" id="1883670" target="_blank">1883670</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30660783">
<a name="30660783"></a>Klinger JR, Elliott CG, Levine DJ, et al. Therapy for pulmonary arterial hypertension in adults: update of the CHEST guideline and expert panel report. <i>Chest</i>. 2019;155(3):565-586. doi:10.1016/j.chest.2018.11.030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/30660783/pubmed" id="30660783" target="_blank">30660783</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23018670">
<a name="23018670"></a>Martínez MV, Rutherford JD. Pulmonary hypertension in pregnancy. <i>Cardiol Rev</i>. 2013;21(4):167-173. doi: 10.1097/CRD.0b013e318275cf01.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/23018670/pubmed" id="23018670" target="_blank">23018670</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26438636">
<a name="26438636"></a>McGinn K, Reichert M. A Comparison of Inhaled Nitric Oxide Versus Inhaled Epoprostenol for Acute Pulmonary Hypertension Following Cardiac Surgery. <i>Ann Pharmacother</i>. 2016;50(1):22-26. doi: 10.1177/1060028015608865.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/26438636/pubmed" id="26438636" target="_blank">26438636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25006402">
<a name="25006402"></a>McIntyre CM, Hanna BD, Rintoul N, Ramsey EZ. Safety of epoprostenol and treprostinil in children less than 12 months of age. <i>Pulm Circ</i>. 2013;3(4):862-869.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/25006402/pubmed" id="25006402" target="_blank">25006402</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19389575">
<a name="19389575"></a>McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation task force on expert consensus documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. <i>J Am Coll Cardiol</i>. 2009;53(17):1573‐1619. doi:10.1016/j.jacc.2009.01.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/19389575/pubmed" id="19389575" target="_blank">19389575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9445406">
<a name="9445406"></a>McLaughlin VV, Genthner DE, Panella MM, et al, “Reduction in Pulmonary Vascular Resistance With Long-Term Epoprostenol (Prostacyclin) Therapy in Primary Pulmonary Hypertension,” <i>N Engl J Med</i>, 1998, 338(5):273-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/9445406/pubmed" id="9445406" target="_blank">9445406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12234951">
<a name="12234951"></a>McLaughlin VV, Shillington A, and Rich S, “Survival in Primary Pulmonary Hypertension: The Impact of Epoprostenol Therapy,” <i>Circulation</i>, 2002, 106(12):1477-82.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/12234951/pubmed" id="12234951" target="_blank">12234951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32115272">
<a name="32115272"></a>Mouratoglou SA, Patsiala A, Feloukidis C, Karvounis H, Giannakoulas G. Transition protocol from subcutaneous treprostinil to intravenous epoprostenol in deteriorating patients with pulmonary arterial hypertension. <i>Int J Cardiol</i>. 2020;306:187-189. doi:10.1016/j.ijcard.2020.02.050<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/32115272/pubmed" id="32115272" target="_blank">32115272</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17965503">
<a name="17965503"></a>Nakayama T, Shimada H, Takatsuki S, et al, “Efficacy and Limitations of Continuous Intravenous Epoprostenol Therapy for Idiopathic Pulmonary Arterial Hypertension in Japanese Children,” <i>Circ J</i>, 2007, 71(11):1785-90.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/17965503/pubmed" id="17965503" target="_blank">17965503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29336971">
<a name="29336971"></a>Rao V, Ghadimi K, Keeyapaj W, Parsons CA, Cheung AT. Inhaled nitric oxide (iNO) and inhaled epoprostenol (iPGI<sub>2</sub>) use in cardiothoracic surgical patients: is there sufficient evidence for evidence-based recommendations?. <i>J Cardiothorac Vasc Anesth</i>. 2018;32(3):1452‐1457. doi:10.1053/j.jvca.2017.12.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/29336971/pubmed" id="29336971" target="_blank">29336971</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15755791">
<a name="15755791"></a>Reisbig KA, Coffman PA, Floreani AA, Bultsma CJ, Olsen KM. Staggered transition to epoprostenol from treprostinil in pulmonary arterial hypertension. <i>Ann Pharmacother</i>. 2005;39(4):739-743. doi:10.1345/aph.1E418<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/15755791/pubmed" id="15755791" target="_blank">15755791</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1603139">
<a name="1603139"></a>Rich S, Kaufmann E, and Levy PS, “The Effect of High Doses of Calcium-channel Blockers on Survival in Primary Pulmonary Hypertension,” <i>N Engl J Med,</i> 1992, 327(2):76-81.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/1603139/pubmed" id="1603139" target="_blank">1603139</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15891429">
<a name="15891429"></a>Rosenzweig EB and Barst RJ, “Idiopathic Pulmonary Arterial Hypertension in Children,” <i>Curr Opin Pediatr</i>, 2005, 17(3):372-80.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/15891429/pubmed" id="15891429" target="_blank">15891429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10199883">
<a name="10199883"></a>Rosenzweig EB, Kerstein D, and Barst RJ, "Long-Term Prostacyclin for Pulmonary Hypertension With Associated Congenital Heart Defects," <i>Circulation</i>, 1999, 99(14):1858-65.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/10199883/pubmed" id="10199883" target="_blank">10199883</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15170869">
<a name="15170869"></a>Rosenzweig EB, Widlitz AC, and Barst RJ, “Pulmonary Arterial Hypertension in Children,” <i>Pediatr Pulmonol</i>, 2004, 38(1):2-22.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/15170869/pubmed" id="15170869" target="_blank">15170869</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7046988">
<a name="7046988"></a>Rubin LJ, Groves BM, Reeves JT, et al, “Prostacyclin-Induced Acute Pulmonary Vasodilation in Primary Pulmonary Hypertension,” <i>Circulation</i>, 1982, 66(2):334-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/7046988/pubmed" id="7046988" target="_blank">7046988</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24516943">
<a name="24516943"></a>Rugolotto S, Beghini R, Cogo I, Sidoti G, Padovani EM, Pietrobelli A. Epoprostenol for very low birth weight (VLBW) infants: a novel dilution protocol. <i>Pediatr Med Chir</i>. 2013;35(5):223-224. doi:10.4081/pmc.2013.31<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/24516943/pubmed" id="24516943" target="_blank">24516943</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28543813">
<a name="28543813"></a>Sabato LA, Salerno DM, Moretz JD, Jennings DL. Inhaled pulmonary vasodilator therapy for management of right ventricular dysfunction after left ventricular assist device placement and cardiac transplantation. <i>Pharmacotherapy</i>. 2017;37(8):944‐955. doi:10.1002/phar.1959<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/28543813/pubmed" id="28543813" target="_blank">28543813</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12204511">
<a name="12204511"></a>Sitbon O, Humbert M, Nunes H, et al, “Long-Term Intravenous Epoprostenol Infusion in Primary Pulmonary Hypertension - Prognostic Factors and Survival,” <i>J Am Coll Cardiol</i>, 2002, 40(40):780-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/12204511/pubmed" id="12204511" target="_blank">12204511</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22139549">
<a name="22139549"></a>Smith JS, Mueller J, Daniels CJ. Pulmonary arterial hypertension in the setting of pregnancy: a case series and standard treatment approach. <i>Lung</i>. 2012;190(2):155-160. doi: 10.1007/s00408-011-9345-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/22139549/pubmed" id="22139549" target="_blank">22139549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7840053">
<a name="7840053"></a>Sueta CA, Gheorghiade M, Adams KF, et al, “Safety and Efficacy of Epoprostenol in Patients With Severe Congestive Heart Failure. Epoprostenol Multicenter Research Group,” <i>Am J Cardiol</i>, 1995, 75(3):34A-43A.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/7840053/pubmed" id="7840053" target="_blank">7840053</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24937180">
<a name="24937180"></a>Taichman DB, Ornelas J, Chung L, et al. Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. <i>Chest</i>. 2014;146(2):449-475. doi: 10.1378/chest.14-0793.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/24937180/pubmed" id="24937180" target="_blank">24937180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24147238">
<a name="24147238"></a>Timofeev J, Ruiz G, Fries M, Driggers RW. Intravenous epoprostenol for management of pulmonary arterial hypertension during pregnancy. <i>AJP Rep</i>. 2013;3(2):71-74. doi: 10.1055/s-0033-1338169.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/24147238/pubmed" id="24147238" target="_blank">24147238</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26668204">
<a name="26668204"></a>Torbic H, Szumita PM, Anger KE, Nuccio P, Lagambina S, Weinhouse G. Clinical and economic impact of formulary conversion from inhaled Flolan to inhaled Veletri for refractory hypoxemia in critically iIl patients. <i>Ann Pharmacother</i>. 2016;50(2):106-112. doi:10.1177/1060028015621308<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/26668204/pubmed" id="26668204" target="_blank">26668204</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23683572">
<a name="23683572"></a>Torbic H, Szumita PM, Anger KE, Nuccio P, LaGambina S, Weinhouse G. Inhaled epoprostenol vs inhaled nitric oxide for refractory hypoxemia in critically ill patients. <i>J Crit Care</i>. 2013;28(5):844-848. doi: 10.1016/j.jcrc.2013.03.006.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/23683572/pubmed" id="23683572" target="_blank">23683572</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10713012">
<a name="10713012"></a>van Heerden PV, Barden A, Michalopoulos N, Bulsara MK, Roberts BL. Dose-response to inhaled aerosolized prostacyclin for hypoxemia due to ARDS. <i>Chest</i>. 2000;117(3):819-827. doi:10.1378/chest.117.3.819<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/10713012/pubmed" id="10713012" target="_blank">10713012</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Veletri.1">
<a name="Veletri.1"></a>Veletri (epoprostenol) [prescribing information]. Titusville, NJ: Actelion Pharmaceuticals US Inc; July 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30614292">
<a name="30614292"></a>Wacker J, Weintraub R, Beghetti M. An update on current and emerging treatments for pulmonary arterial hypertension in childhood and adolescence. <i>Expert Rev Respir Med</i>. 2019;13(2):205-215. doi:10.1080/17476348.2019.1565998<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/30614292/pubmed" id="30614292" target="_blank">30614292</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8105216">
<a name="8105216"></a>Walmrath D, Schneider T, Pilch J, et al, “Aerosolised Prostacyclin in Adult Respiratory Distress Syndrome,” <i>Lancet</i>, 1993, 342(8877):961-2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/8105216/pubmed" id="8105216" target="_blank">8105216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32973104">
<a name="32973104"></a>Walsh BK. Inhaled pulmonary vasodilators in the neonatal and pediatric ICU. <i>Respir Care</i>. 2020;65(10):1611-1623. doi:10.4187/respcare.08265<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/32973104/pubmed" id="32973104" target="_blank">32973104</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12570125">
<a name="12570125"></a>Widlitz A and Barst RJ, “Pulmonary Arterial Hypertension in Children,”<i>Eur Respir J</i>, 2003, 21(1):155-76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/12570125/pubmed" id="12570125" target="_blank">12570125</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30472016">
<a name="30472016"></a>Windsor J, Ricci M, Aldoss O, Nakamura Y, Ramakrishna H. Simultaneous intraoperative delivery of inhaled epoprostenol and nitric oxide in a neonate for atrial septal defect closure: first report of a novel technique<i>. J Cardiothorac Vasc Anesth</i>. 2019;33(10):2755-2759. doi:10.1053/j.jvca.2018.10.037<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/30472016/pubmed" id="30472016" target="_blank">30472016</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35049017">
<a name="35049017"></a>Wu Y, Liu HM, Gu L, Li QW, Zhu L. Prostacyclins and pulmonary arterial hypertension in children. <i>Eur Rev Med Pharmacol Sci</i>. 2022;26(1):37-45. doi:10.26355/eurrev_202201_27745<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/35049017/pubmed" id="35049017" target="_blank">35049017</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8970353">
<a name="8970353"></a>Zwissler, B, Kemming G, Habler O, et al, “Inhaled Prostacyclin (PGI2) Versus Inhaled Nitric Oxide in Adult Respiratory Distress Syndrome,” <i>Am J Respir Crit Care Med</i>, 1996, 154(6 Pt 1):1671-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/8970353/pubmed" id="8970353" target="_blank">8970353</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13139 Version 212.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
